ArticlePhotochemistry and photobiology
Evaluating photodynamic therapy response in head and neck cancer with EGFR-targeted paired-agent imaging.
Article in Photochemistry and photobiology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Head and neck cancer (HNC) affects thousands globally, with high morbidity rates due to standard treatments like surgery and radiation. Photodynamic therapy (PDT) has shown great promise as a less destructive alternative, selectively targeting tumors while preserving healthy tissue. However, assessing treatment response in the days after PDT is challenging due to significant inflammation and the subsequent vascular shutdown of the tumor. We hypothesize that fluorescence paired-agent imaging (PAI) can provide early molecular insights within 24 h of PDT to evaluate treatment efficacy. PAI utilizes two fluorescent agents to correct for perfusion-related changes, allowing for accurate quantification of key signaling proteins. Specifically, we tracked epidermal growth factor receptor (EGFR) response to benzoporphyrin derivative monoacid (BPD)-PDT at 690 nm, with light fluences ranging from 0 to 100 J/cm
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.